Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Consumption of high-dose statins in patients older than 65 years in the Republic of Croatia in the period 2005 - 2015 (CROSBI ID 294747)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Grgurević, Dijana ; Grgurević, Joško ; Bačić Vrca, Vesna ; Marušić, Srećko ; Marinović, Ivana Consumption of high-dose statins in patients older than 65 years in the Republic of Croatia in the period 2005 - 2015 // International journal of clinical pharmacology and therapeutics, 59 (2021), 2; 127-137. doi: 10.5414/CP203572

Podaci o odgovornosti

Grgurević, Dijana ; Grgurević, Joško ; Bačić Vrca, Vesna ; Marušić, Srećko ; Marinović, Ivana

engleski

Consumption of high-dose statins in patients older than 65 years in the Republic of Croatia in the period 2005 - 2015

Objective: Patients over 65 years of age on high- dose statins are most sensitive to the development of adverse effects of statins. The objective of this study is to analyze the consumption of high- dose statins in this patient group in Croatia in the period of 2005 – 2015. Materials and methods: For the period of January 1, 2005 to December 31, 2015, the Croatian Institute for Health Insurance provided us with the total number of: all insured, insured over 65 years of age, insured using statins, insured using high-dose statins, insured over 65 using statins, insured over 65 using high- dose statins, number of packages dispensed through all community pharmacies for all statins registered in Croatia divided by year and sex. Studied high- dose statins were: simvastatin 40 mg ; atorvastatin 40 mg, 60 mg, 80 mg ; fluvastatin 80 mg ; rosuvastatin 40 mg. The yearly consumption of each form of statin was calculated in DDD/1, 000 insured/day and was statistically processed. Results: The consumption of all statins increased by 194%, while the consumption of high-dose statins in patients over 65 increased by 296%. The number of all patients on statin therapy increased by 58%, the number of patients over 65 on statin therapy increased by 87%, and the number of patients over 65 on high-dose statins increased by 326%. 60% of all patients over 65 receiving high- dose statins were women. The most used high-dose statins were atorvastatin and simvastatin. Conclusion: Consumption of all statins increased, mostly high-dose statins in the 65+ age group, the most sensitive population for adverse effects. The number of 65+ patients on high-dose statins grew much faster than the general statin user group, thus increasing the risk potential. Women are dominating all age and dose groups of statin users.

statins ; elderly patients

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

59 (2)

2021.

127-137

objavljeno

0946-1965

10.5414/CP203572

Povezanost rada

Farmacija

Poveznice
Indeksiranost